Abstract
Twenty-five B-cell-depleted patients (24 following anti-CD19/20 therapy) diagnosed with coronavirus disease 2019 had been symptomatic for a median of 26 days but remained antibody negative. All were treated with convalescent plasma with high neutralizing antibody titers. Twenty-one (84%) recovered, indicating the potential therapeutic effects of this therapy in this particular population.
Trial registration: ClinicalTrials.gov NCT04375098 .
Keywords: 19; 2; B; COVID; CoV; SARS; cell depletion; convalescent plasma; immunodeficiency.
All Keywords
【저자키워드】 convalescent plasma, SARS, COVID, CoV, 19, 2, immunodeficiency., B, cell depletion, 【초록키워드】 coronavirus disease, therapy, antibody, immunodeficiency, symptomatic, convalescent, neutralizing antibody titers, therapeutic effect, Cell, remained, diagnosed, median, treated, B-cell-depleted patient, 【제목키워드】 Effect,
【저자키워드】 convalescent plasma, SARS, COVID, CoV, 19, 2, immunodeficiency., B, cell depletion, 【초록키워드】 coronavirus disease, therapy, antibody, immunodeficiency, symptomatic, convalescent, neutralizing antibody titers, therapeutic effect, Cell, remained, diagnosed, median, treated, B-cell-depleted patient, 【제목키워드】 Effect,
{{{ 추상적인 }}}
2019년 코로나바이러스 질병으로 진단된 25명의 B 세포 고갈 환자(항-CD19/20 치료 후 24명)는 중앙값 26일 동안 증상이 있었지만 항체 음성을 유지했습니다. 모두 중화 항체 역가가 높은 회복기 혈장으로 처리되었습니다. 21명(84%)이 회복되었으며, 이는 이 특정 집단에서 이 요법의 잠재적인 치료 효과를 나타냅니다.
{{ 시험 등록: }} ClinicalTrials.gov NCT04375098 .
{{ 키워드: }} 19; 2; 비; 코로나; 코로나바이러스; 사스; 세포 고갈; 회복기 혈장; 면역 결핍.